Circumcision and HIV
Male circumcision reduces the risk of HIV transmission from women to men. In 2011, the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) stated that male circumcision is an efficacious intervention for HIV prevention if carried out by medical professionals under safe conditions. The United States Centers for Disease Control and Prevention (CDC) states that circumcision reduces the risk that a man will acquire HIV and other sexually transmitted infections (STIs) from an infected female partner.
A meta-analysis of data from fifteen observational studies of men who have sex with men found "insufficient evidence that male circumcision protects against HIV infection or other STIs". The CDC concludes "There are as yet no convincing data to help determine whether male circumcision will have any effect on HIV risk for men who engage in anal sex with either a female or male partner, as either the insertive or receptive partner."
- Male circumcision should now be recognized as an efficacious intervention for HIV prevention.
- Promoting male circumcision should be recognized as an additional, important strategy for the prevention of heterosexually acquired HIV infection in men.
Kim Dickson, coordinator of the working group that authored the report, commented:
- Male circumcision "would have greatest impact" in countries where the HIV infection rate among heterosexual males is greater than 15 percent and fewer than 20 percent of males are circumcised.
- The procedure must be done by a trained health care professional.
- Protection is incomplete. Men must continue to use condoms and limit the number of sexual partners.
- Newly circumcised men should abstain from sex for at least six weeks.
The World Health Organization (WHO) said: "Although these results demonstrate that male circumcision reduces the risk of men becoming infected with HIV, the UN agencies emphasize that it does not provide complete protection against HIV infection. Circumcised men can still become infected with the virus and, if HIV-positive, can infect their sexual partners. Male circumcision should never replace other known effective prevention methods and should always be considered as part of a comprehensive prevention package, which includes correct and consistent use of male or female condoms, reduction in the number of sexual partners, delaying the onset of sexual relations, and HIV testing and counselling."
Men who have sex with men
A 2008 meta-analysis of gay and bisexual men (52% circumcised) found that the rate of HIV infection was not lower among men who were circumcised. For men who engaged primarily in insertive anal sex, no effect was observed. Observational studies included in the meta-analysis that were conducted prior to the introduction of highly active antiretroviral therapy in 1996 demonstrated a protective effect for circumcised MSM against HIV infection.
In 2011, UNAIDS prioritized 14 high HIV prevalence countries in eastern and southern Africa, with a goal of circumcising 80% of men (20.8 million) by the end of 2016. In parallel, WHO developed a Framework for evaluating new, simpler circumcision techniques, which gave impetus to the development of two new devices (Prepex and Shang Ring) that are currently being scaled-up in the 14 high HIV prevalence countries. Overall, 14.5 million males were circumcised as of the end of 2016. UNAIDS' Fast-Track Plan for ending the AIDS Epidemic by 2030 calls for an additional 25 million circumcisions in these high-priority countries by 2020, which will require to 5 million procedures per year, nearly double the current rate. To reach this goal, UNAIDS is counting on advances in circumcision techniques.
Newly circumcised men must refrain from sexual activity until the wounds are fully healed. Some circumcised men might have a false sense of security that could lead to increased risky sexual behavior.
Mechanism of action
Experimental evidence supports the theory that Langerhans cells (part of the human immune system) in foreskin may be a source of entry for the HIV virus. Excising the foreskin removes a main entry point for the HIV virus.
Hypotheses and epidemiologic studies
Valiere Alcena, in a 1986 letter to the New York State Journal of Medicine, noted that low rates of circumcision in parts of Africa had been linked to the high rate of HIV infection. Aaron J. Fink several months later also proposed that circumcision could have a preventive role when the New England Journal of Medicine published his letter, "A possible explanation for heterosexual male infection with AIDS," in October, 1986. Alcena later said that Fink had expropriated his ideas.
By 2000, over 40 epidemiological studies had been conducted to investigate the relationship between circumcision and HIV infection. A meta-analysis conducted by researchers at the London School of Hygiene & Tropical Medicine examined 27 studies of circumcision and HIV in sub-Saharan Africa and concluded that these showed circumcision to be "associated with a significantly reduced risk of HIV infection" that could form part of a useful public health strategy.
A 2005 review of 37 observational studies expressed reservations about the conclusion because of possible confounding factors, since they were all observational (and not experimental) studies. The authors stated that three randomized controlled trials then underway in Africa would provide "essential evidence" about the effects of circumcision on preventing HIV.
Randomized controlled trials in Africa
The first trial to publish, in 2005, was that from South Africa, named ANRS-1265 or the "Orange Farm trial". After 18 months, there were 20 HIV infections (incidence rate = 0.85 per 100 person-years) in the intervention group and 49 (2.1 per 100 person-years) in the control group, a finding which led to suspension of the trial on ethical grounds. The other two African trials were also halted on ethical grounds, again because those in the circumcised group had a lower rate of new HIV infections than the control group.
The Orange Farm trial report concluded that circumcision offered protection against HIV infection "equivalent to what a vaccine of high efficacy would have achieved".
A 2009 systematic review from the Cochrane Collaboration included these 3 randomized controlled trials. It provided strong evidence that medical male circumcision reduces the acquisition of HIV by heterosexual men by about 60%, while adverse events are rare, and recommended inclusion of male circumcision into current HIV prevention guidelines.
Society and culture
The prevalence of circumcision varies across Africa. Studies were conducted to assess the acceptability of promoting circumcision; in 2007, country consultations and planning to scale up male circumcision programmes took place in Botswana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, Tanzania, Zambia and Zimbabwe.
The UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male Circumcision for HIV Prevention found "large benefits" of circumcision in settings with high HIV prevalence and low circumcision prevalence. The Group estimated "one HIV infection being averted for every five to 15 male circumcisions performed, and costs to avert one HIV infection ranging from US$150 to US$900 using a 10-y time horizon". The World Health Organisation states that circumcision is "highly cost-effective" in comparison to other HIV interventions when data from the South African trial are used, but less cost-effective when data from the Ugandan trial are used.
- Krieger JN (May 2011). "Male circumcision and HIV infection risk". World Journal of Urology (Review). 30 (1): 3–13. doi:10.1007/s00345-011-0696-x. PMID 21590467.
- Siegfried N, Muller M, Deeks JJ, Volmink J (2009). Siegfried, Nandi, ed. "Male circumcision for prevention of heterosexual acquisition of HIV in men". Cochrane Database of Systematic Reviews (Review) (2): CD003362. doi:10.1002/14651858.CD003362.pub2. PMID 19370585.
- "Male circumcision: Global trends and determinants of prevalence, safety and acceptability" (PDF). World Health Organization. 2007. Retrieved 2009-03-04.
- "New Data on Male Circumcision and HIV Prevention: Policy and Programme Implications" (PDF). World Health Organization. March 28, 2007. Retrieved 2007-08-13.
- "WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention". World Health Organisation. March 2007.
- "Male Circumcision". Centers for Disease Control and Prevention. 2013. Archived from the original on 2013-12-21.
- Millett GA, Flores SA, Marks G, Reed JB, Herbst JH (October 2008). "Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis". JAMA (Meta-analysis). 300 (14): 1674–84. doi:10.1001/jama.300.14.1674. PMID 18840841.
- "WHO hails circumcision as vital in HIV fight". New Scientist. March 28, 2007. Retrieved 2008-09-18.
- "WHO and UNAIDS Secretariat welcome corroborating findings of trials assessing impact of male circumcision on HIV risk". World Health Organization. February 23, 2007. Retrieved 2007-02-23.
- Sharma, SC; Raison, N; Khan, S; Shabbir, M; Dasgupta, P; Ahmed, K (12 December 2017). "Male Circumcision for the Prevention of HIV Acquisition: A Meta-Analysis". BJU International. 121 (4): 515–526. doi:10.1111/bju.14102. PMID 29232046.
- Wiysonge, CS; Kongnyuy, EJ; Shey, M; Muula, AS; Navti, OB; Akl, EA; Lo, YR (15 June 2011). "Male circumcision for prevention of homosexual acquisition of HIV in men". The Cochrane Database of Systematic Reviews (6): CD007496. doi:10.1002/14651858.CD007496.pub2. PMID 21678366.
- Joint strategic action framework to accelerate the scale-up of voluntary medical male circumcision for HIV prevention in Eastern and Southern Africa, 2012-2016. WHO. 2011.
- Framework for Clinical Evaluation of Devices for Adult Male Circumcision (PDF) (Report). WHO. 2007.
- Voluntary medical male circumcision for HIV prevention in 14 priority countries in eastern and southern Africa, Progress brief (PDF) (Report). WHO. 2017.
- "Voluntary medical male circumcision: a core campaign to reach the Fast-Track Targets". UNAIDS. 2016.
- Kalichman, Seth; Lisa Eaton; Steven Pinkerton (March 2007). "Circumcision for HIV Prevention: Failure to Fully Account for Behavioral Risk Compensation". PLoS Medicine. 4 (3): 138. doi:10.1371/journal.pmed.0040138. PMC 1831748. PMID 17388676.
- Weiss HA, Dickson KE, Agot K, Hankins CA (2010). "Male circumcision for HIV prevention: current research and programmatic issues". AIDS (Randomized controlled trial). 24 Suppl 4: S61–9. doi:10.1097/01.aids.0000390708.66136.f4. PMC 4233247. PMID 21042054.
- Alcena, V (19 October 2006). "AIDS in Third World countries". PLOS Medicine (Comment).
- Alcena, V (August 1986). "AIDS in Third World countries". New York State Journal of Medicine (Letter). 86 (8): 446.
- Fink AJ (October 1986). "A possible explanation for heterosexual male infection with AIDS". N. Engl. J. Med. (Letter). 315 (18): 1167. doi:10.1056/nejm198610303151818. PMID 3762636.
- Szabo R, Short RV (June 2000). "How does male circumcision protect against HIV infection?". BMJ (Review). 320 (7249): 1592–4. doi:10.1136/bmj.320.7249.1592. PMC 1127372. PMID 10845974.
- Weiss HA, Quigley MA, Hayes RJ (October 2000). "Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis" (PDF). AIDS (Meta-analysis). 14 (15): 2361–70. doi:10.1097/00002030-200010200-00018. PMID 11089625.
- Siegfried N, Muller M, Deeks J, et al. (March 2005). "HIV and male circumcision--a systematic review with assessment of the quality of studies". The Lancet Infectious Diseases (Review). 5 (3): 165–73. doi:10.1016/S1473-3099(05)01309-5. PMID 15766651.
- Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A (November 2005). "Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial". PLoS Med. (Randomized controlled trial). 2 (11): e298. doi:10.1371/journal.pmed.0020298. PMC 1262556. PMID 16231970.
- Bailey RC, Moses S, Parker CB, et al. (February 2007). "Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial". Lancet (Randomized controlled trial). 369 (9562): 643–56. doi:10.1016/S0140-6736(07)60312-2. PMID 17321310.
- Gray RH, Kigozi G, Serwadda D, et al. (February 2007). "Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial". Lancet (Randomized controlled trial). 369 (9562): 657–66. doi:10.1016/S0140-6736(07)60313-4. PMID 17321311.
- Siegfried, Nandi; Muller, Martie; Deeks, Jonathan J.; Volmink, Jimmy (2009-04-15). "Male circumcision for prevention of heterosexual acquisition of HIV in men". The Cochrane Database of Systematic Reviews (2): CD003362. doi:10.1002/14651858.CD003362.pub2. ISSN 1469-493X. PMID 19370585.
- Marck, Jeff (1997). "Aspects of male circumcision in subequatorial African culture history" (PDF). Health Transition Review (Review). 7 (Supplement): 337–60. PMID 10173099. Retrieved 2008-10-16.
- "Male circumcision: global trends and determinants of prevalence, safety and acceptability" (PDF). Who/Unaids. 2007. Retrieved 2008-10-16.
- "Towards Universal access: Scaling up priority HIV/AIDS interventions in the health sector" (PDF). Who/Unaids/Unicef: 75. 2008. Retrieved 2008-10-16.
- UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male Circumcision for HIV Prevention (2009). "Male Circumcision for HIV Prevention in High HIV Prevalence Settings: What Can Mathematical Modelling Contribute to Informed Decision Making?". PLoS Med (Review). 6 (9): e1000109. doi:10.1371/journal.pmed.1000109. PMC 2731851. PMID 19901974.
- Chang LW, Serwadda D, Quinn TC, Wawer MJ, Gray RH, Reynolds SJ (January 2013). "Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects". Lancet Infect Dis (Review). 13 (1): 65–76. doi:10.1016/S1473-3099(12)70273-6. PMC 3792852. PMID 23257232.
- Darby R, Van Howe R (October 2011). "Not a surgical vaccine: there is no case for boosting infant male circumcision to combat heterosexual transmission of HIV in Australia". Aust N Z J Public Health (Review). 35 (5): 459–65. doi:10.1111/j.1753-6405.2011.00761.x. PMID 21973253.
- Reed JB, Njeuhmeli E, Thomas AG, et al. (August 2012). "Voluntary medical male circumcision: an HIV prevention priority for PEPFAR". J. Acquir. Immune Defic. Syndr. (Review). 60 Suppl 3: S88–95. doi:10.1097/QAI.0b013e31825cac4e. PMC 3663585. PMID 22797745.
- Ryan CA, Conly SR, Stanton DL, Hasen NS (August 2012). "Prevention of sexually transmitted HIV infections through the President's Emergency Plan for AIDS Relief: a history of achievements and lessons learned". J. Acquir. Immune Defic. Syndr. (Review). 60 Suppl 3: S70–7. doi:10.1097/QAI.0b013e31825e3149. PMID 22797743.
- Uthman OA, Popoola TA, Uthman MM, Aremu O (2010). Van Baal, Pieter H. M, ed. "Economic evaluations of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a systematic review". PLoS ONE (Review). 5 (3): e9628. Bibcode:2010PLoSO...5.9628U. doi:10.1371/journal.pone.0009628. PMC 2835757. PMID 20224784.
- World Health Organization
- "Voluntary medical male circumcision for HIV prevention". World Health Organization. July 2012. Retrieved January 11, 2014.
- "Global health sector strategy on HIV/AIDS 2011-2015" (PDF). World Health Organization. 2011. Retrieved January 11, 2014.
- "Guideline on the use of devices for adult male circumcision for HIV prevention". World Health Organization. October 2013. Retrieved January 11, 2014.
- "Male circumcision for HIV prevention". World Health Organization. Retrieved January 11, 2014.